F-1: Biodexa Pharmaceuticals PLC Files F-1 for $18M Offering

Biodexa Pharmaceuticals PLC is registering a public offering of up to $18 million in units, including American Depositary Shares and Series L Warrants, to fund its clinical development programs.

Summary

• Biodexa Pharmaceuticals PLC is offering up to 3,377,110 Units, each consisting of one American Depositary Share (ADS) and one Series L Warrant, or Pre-Funded Units for purchasers exceeding beneficial ownership limits.
• The assumed combined public offering price is $5.33 per Unit, based on the NASDAQ closing price on November 12, 2025, aiming for gross proceeds of up to $18.0 million.
• Net proceeds are estimated at approximately $15.5 million after deducting placement agent fees and offering expenses.
• Series L Warrants have an initial exercise price of 225% of the public offering price and expire 2.5 years after issuance, featuring anti-dilution, cashless exercise, and zero cash exercise price options.
• The zero cash exercise option allows holders to receive an aggregate number of Depositary Shares equal to twice what would be issuable upon a cash exercise, without additional cash payment, making it highly unlikely the company will receive cash from these exercises.
• Exercise prices for Series L Warrants will reset on the 5th and 10th trading days after issuance, subject to floor prices of 50% and 30% of the Latest NASDAQ Closing Price, respectively.
• Pre-Funded Warrants have a nominal exercise price of $0.0001 per ADS and are immediately exercisable until fully exercised.
• The company is a clinical-stage biopharmaceutical firm focused on eRapa (for FAP and NMIBC) and tolimidone (for T1D), while the MTX110 program (for rare/orphan brain cancers) has been de-prioritized due to resource constraints.
• Cash and cash equivalents as of September 30, 2025, were £2.79 million (unaudited).
• As of June 30, 2025, there were 61,952,308,922 Ordinary Shares outstanding; if all shares offered were issued, they would represent approximately 98.9% of total outstanding Ordinary Shares.
• Maxim Group LLC, the exclusive placement agent, will receive a 7.0% cash fee of gross proceeds, a 1.0% non-accountable expense allowance, and Placement Agent Warrants to purchase 5.0% of the units sold.

Sentiment

Score: 2

Explanation: The filing details a highly dilutive capital raise with significant risks to existing shareholders, including potential delisting and minimal cash proceeds from warrants. While there is some positive clinical progress, the financial implications of this offering are overwhelmingly negative for current equity holders.

Positives

• eRapa received Fast Track designation from the FDA on February 10, 2025, intended to facilitate development and expedite review for serious conditions with unmet medical needs.
• eRapa was granted Orphan Drug Designation in Europe for Familial Adenomatous Polyposis (FAP) on May 12, 2025, which provides 10 years of marketing exclusivity and special incentives.
• An additional $3.0 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) was received in May 2025 to support the registrational Phase 3 program of eRapa in FAP, expected to fund substantially all costs.
• The first clinical study site for the Phase 3 FAP study of eRapa was activated on June 25, 2025, and is actively screening patients.
• The European Medicines Agency (EMA) approved the Clinical Trial Application (CTA) for the Phase 3 FAP study in Europe on November 3, 2025.
• The first patient was recruited in the Phase 2a dose confirming study of tolimidone for Type 1 Diabetes (T1D) on June 4, 2025.
• The company's strategy focuses on developing clinical assets to proof-of-concept stage before seeking partners for later-stage development and commercialization.

Negatives

• The offering presents significant potential for dilution to existing shareholders, with new shares potentially representing approximately 98.9% of total outstanding Ordinary Shares.
• The company explicitly states it is 'highly unlikely' to receive additional funds from the exercise of Series L Warrants due to the zero cash exercise price option.
• The MTX110 program for rare/orphan brain cancers has been de-prioritized due to resource constraints.
• There is no established trading market for the Units, Pre-Funded Units, Series L Warrants, or Pre-Funded Warrants, which will limit their liquidity.
• The offering carries a risk of an immediate trading halt or delisting from NASDAQ due to public interest concerns regarding the dilutive nature of the transaction.
• There is a risk that the Depositary Share price could fall below NASDAQ's minimum bid price requirement ($1.00 per share) as a result of the offering, potentially leading to delisting.
• The historical net tangible book value per Depositary Share as of June 30, 2025, was $12.82, which is projected to decrease to $5.86 after the offering, representing an immediate decrease of $6.96 per Depositary Share for existing shareholders.
• The company has never paid cash dividends on its Ordinary Shares and does not anticipate doing so in the foreseeable future, meaning investors must rely on share price appreciation for returns.
• Management has broad discretion in the application of the net proceeds, and there is no guarantee that these funds will be used effectively or yield a favorable return.
• This is a 'best efforts' offering, meaning there is no minimum amount of securities required to be sold, and the company may not raise the amount of capital it believes is required for its business plans.
• A dispute with a former advisor regarding fees was resolved through a settlement, with a payment made on September 29, 2025, indicating a past contingent liability.

Risks

• The sale of a substantial number of Depositary Shares in this offering could cause the price of the Depositary Shares to decline and result in substantial dilution to existing shareholders.
• Future equity offerings may lead to further dilution for current investors.
• Sales of a substantial number of Depositary Shares in the public markets, or the perception of such sales, could depress the market price of the Depositary Shares.
• Shareholders must rely on the appreciation of the value of Depositary Shares for any return on investment, as the company does not intend to declare cash dividends in the foreseeable future.
• Management has broad discretion and flexibility in how the net proceeds from this offering are used, which may not prove effective.
• The liquidity and trading volume of the Depositary Shares could be low, adversely impacting the trading price and ability to raise capital.
• As a 'best efforts' offering, there is no guarantee that the company will raise the amount of capital required for its business plans.
• The offering may result in an immediate trading halt or delisting of Depositary Shares from NASDAQ due to public interest concerns regarding the dilutive nature of the transaction or other reasons.
• The offering may cause the price of Depositary Shares to decline and fall below NASDAQ's minimum bid price requirement, potentially leading to delisting.
• The company will likely not receive any additional funds upon the exercise of the Series L Warrants due to the zero cash exercise price option.
• There is no public market for the warrants being offered, limiting their liquidity.
• Holders of Pre-Funded Warrants and Series L Warrants will have no rights as Depositary Share holders until such warrants are exercised.
• The Pre-Funded Warrants and Series L Warrants are speculative in nature and may not have value if the Depositary Shares do not exceed the exercise price.
• The terms of the warrants could impede the company's ability to enter into certain transactions or obtain additional financing.
• The company may be required to repurchase Series L Warrants in the event of certain Fundamental Transactions, which could materially adversely affect its financial condition.
• Classification as a Passive Foreign Investment Company (PFIC) could result in various adverse United States tax consequences for U.S. Holders.
• Fluctuations in foreign currency exchange rates could impact the value of distributions.
• The company may not be able to renew its existing insurance coverage or obtain similar coverage from similar insurers without a significant increase in cost.
• The company and its subsidiaries may not be in compliance with all applicable U.S. federal, state, local, and foreign laws and regulations relating to employment, environmental protection, occupational health and safety, product quality and safety, and data privacy, which could have a Material Adverse Effect.
• Intellectual Property Rights may expire, terminate, be abandoned, or be found invalid or unenforceable, which could have a Material Adverse Effect.
• There is a risk of litigation or regulatory matters affecting the company or its subsidiaries.

Future Outlook

The company intends to use the net proceeds from this offering to fund its development programs, for working capital, and other general corporate purposes. It plans to develop its clinical assets to the proof-of-concept stage before seeking partners for more expensive, later-stage development and commercialization. The company expects to begin enrolling a multi-center registrational Phase 3 trial in FAP in the third quarter of 2025.

Management Comments

• We believe it is highly unlikely that a holder of the Series L Warrants would pay an exercise price in cash to receive one Depositary Share when the holder could instead choose the zero cash exercise price option and pay no cash to receive up to 15 Depositary Shares if the exercise price decreases to and equals the floor price at the time of such election.
• As a result, we will likely not receive any additional funds and do not expect to receive any additional funds upon the exercise of the Series L Warrants.

Industry Context

Biodexa Pharmaceuticals PLC operates as a clinical-stage biopharmaceutical company, strategically shifting its focus from drug delivery technologies to therapeutics, particularly for rare/orphan indications. The company's pipeline includes eRapa for Familial Adenomatous Polyposis (FAP) and non-muscle invasive bladder cancer (NMIBC), and tolimidone for Type 1 Diabetes (T1D). The global glioblastoma multiforme (GBM) treatment market, a previous focus for the company's de-prioritized MTX110, was valued at approximately $2.46 billion in 2022, with an expected growth of 9.7% per annum through 2030. The company leverages regulatory incentives like FDA Fast Track and European Orphan Drug Designation, which are critical for accelerating development and securing market exclusivity in the rare disease space.

Comparison to Industry Standards

• The global Glioblastoma Multiforme (GBM) treatment market was valued at approximately $2.46 billion in 2022, with expected growth of 9.7% per annum through 2030, indicating a significant market opportunity for brain cancer therapies, though Biodexa's MTX110 program in this area has been de-prioritized.
• Type 1 Diabetes (T1D) affects approximately 8.4 million people worldwide, with about 500,000 new diagnoses annually, highlighting a substantial patient population for tolimidone.
• Familial Adenomatous Polyposis (FAP) has a reported incidence of one in 5,000 to 10,000 in the United States and one in 11,300 to 37,600 in Europe, classifying it as a rare disease, which aligns with Biodexa's focus on orphan indications.
• Non-muscle invasive bladder cancer (NMIBC) is the fourth most common cancer in men (10.1 per 100,000) and 2.5 per 100,000 in women, representing a notable cancer indication for eRapa.
• Diffuse Midline Glioma (DMG) has a median survival of approximately 10 months, underscoring the high unmet medical need in this aggressive rare brain cancer, where MTX110 was being studied before de-prioritization.

Corporate Governance

Legal Proceedings

• A dispute with a former advisor regarding fees was resolved through a settlement, with a payment made to the former advisor on September 29, 2025.

Stakeholder Impact

• Shareholders will experience significant dilution from the offering and warrant exercises, with new shares potentially representing approximately 98.9% of total outstanding Ordinary Shares.
• Existing shareholders will see an immediate decrease in net tangible book value per Depositary Share from $12.82 to $5.86.
• No cash dividends are expected in the foreseeable future, meaning shareholders must rely on capital appreciation for returns.
• There is a risk of NASDAQ delisting due to public interest concerns over dilution and potential failure to meet minimum bid price requirements, which would negatively impact liquidity and share value for shareholders.
• Investors participating in this offering will experience an immediate accretion of $0.53 per Depositary Share in net tangible book value.
• The placement agent, Maxim Group LLC, will receive substantial compensation, including a 7.0% cash fee, a 1.0% non-accountable expense allowance, and Placement Agent Warrants equal to 5.0% of the units sold.
• The placement agent also has a right of first refusal for future equity, equity-linked, or debt offerings if the current offering generates at least $10.0 million in gross proceeds, potentially impacting future financing arrangements.
• Employees and directors are subject to lock-up agreements for 45 days post-closing, restricting their ability to sell company securities.

Next Steps

• Complete the public offering of Units and/or Pre-Funded Units.
• Utilize the net proceeds from the offering to fund development programs, for working capital, and other general corporate purposes.
• Continue the Phase 2 study of eRapa in NMIBC, which is being conducted as an Investigator Initiated Trial (IIT) by the University of Texas, San Antonio.
• Proceed with enrolling patients in the multi-center registrational Phase 3 clinical study of eRapa in FAP across clinical sites in the United States and Europe.
• Continue the Phase 2a dose confirming study of tolimidone for T1D, measuring C-peptide levels and HbA1c.
• Seek to license products to partners for later-stage development and commercialization once proof-of-concept has been established.
• Maintain the listing or quotation of American Depositary Shares (ADSs) on the NASDAQ Capital Market and comply with all listing and maintenance requirements.
• File all required reports and documents with the SEC and the Trading Market on a timely basis.

Key Dates

Recommendation

The offering is structured in a highly dilutive manner, with the potential for new shares to represent nearly 99% of the total outstanding shares. The company explicitly states it is 'highly unlikely' to receive cash from the exercise of Series L Warrants, indicating a significant capital raise without corresponding cash inflow from future warrant exercises. The immediate decrease in net tangible book value for existing shareholders is substantial. Combined with the 'best efforts' nature of the offering (no guarantee of raising sufficient capital), the de-prioritization of a clinical program (MTX110) due to resource constraints, and the explicit risks of NASDAQ delisting due to dilution and minimum bid price concerns, the financial outlook for existing shareholders is extremely poor. While there are some positive clinical developments, the financial structure of this offering and the associated risks suggest a strong negative impact on shareholder value.

Keywords

Biodexa Pharmaceuticals, BDRX, SEC Filing, F-1, Public Offering, American Depositary Shares, ADSs, Warrants, Series L Warrants, Pre-Funded Warrants, Dilution, Biopharmaceutical, Clinical Stage, eRapa, Familial Adenomatous Polyposis, FAP, Non-Muscle Invasive Bladder Cancer, NMIBC, Tolimidone, Type 1 Diabetes, T1D, MTX110, Brain Cancer, Orphan Drug, Fast Track, NASDAQ, Capital Raise, Financial Health, Corporate Governance, Risk Management